These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 1786065)

  • 1. Reversal of acute glomerular renal allograft rejection: a possible effect of OKT3.
    Hibberd AD; Nanra RS; White KH; Trevillian PR
    Transpl Int; 1991 Dec; 4(4):246-8. PubMed ID: 1786065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection.
    Woodle ES; Xu D; Zivin RA; Auger J; Charette J; O'Laughlin R; Peace D; Jollife LK; Haverty T; Bluestone JA; Thistlethwaite JR
    Transplantation; 1999 Sep; 68(5):608-16. PubMed ID: 10507477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of OKT3 as primary therapy for histologically confirmed acute renal allograft rejection.
    Kamath S; Dean D; Peddi VR; Schroeder TJ; Alexander JW; Cavallo T; First MR
    Transplantation; 1997 Nov; 64(10):1428-32. PubMed ID: 9392306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of OKT3 monoclonal antibody and anti-thymocyte globulin in the treatment of steroid-resistant acute allograft rejection in pediatric renal transplants.
    Mochon M; Kaiser B; Palmer JA; Polinsky M; Flynn JT; Caputo GC; Baluarte HJ
    Pediatr Nephrol; 1993 Jun; 7(3):259-62. PubMed ID: 8518094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [OKT3 treatment of refractory renal allograft rejection].
    Xu J; Ma J; Bai X
    Zhonghua Wai Ke Za Zhi; 1997 Apr; 35(4):223-5. PubMed ID: 10374543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of first acute rejection episode and severity of rejection on cadaveric renal allograft survival.
    Hariharan S; Alexander JW; Schroeder TJ; First MR
    Clin Transplant; 1996 Dec; 10(6 Pt 1):538-41. PubMed ID: 8996775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of microvascular injury on steroid and OKT3 response in renal allograft rejection.
    Ozdemir BH; Demirhan B; Ozdemir FN; Dalgiç A; Haberal M
    Transplantation; 2004 Sep; 78(5):734-40. PubMed ID: 15371678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of renal allograft rejection with T10B9.1A31 or OKT3: final analysis of a phase II clinical trial.
    Waid TH; Lucas BA; Thompson JS; McKeown JW; Brown S; Kryscio R; Skeeters LJ
    Transplantation; 1997 Jul; 64(2):274-81. PubMed ID: 9256187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. OKT3 escalating dose regimens provide effective therapy for renal allograft rejection.
    Woodle ES; Bruce DS; Josephson M; Cronin D; Newell KA; Millis JM; Piper JB; O'Laughlin R; Thistlethwaite JR
    Clin Transplant; 1996 Aug; 10(4):389-95. PubMed ID: 8884115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. OKT3 treatment of cardiac allograft rejection.
    Haverty TP; Sanders M; Sheahan M
    J Heart Lung Transplant; 1993; 12(4):591-8. PubMed ID: 8369321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of OKT3 as primary therapy for histologically confirmed acute renal allograft rejection in simultaneous kidney and pancreas transplant recipients.
    Peddi VR; Kamath S; Schroeder TJ; Munda R; First MR
    Transplant Proc; 1998 Mar; 30(2):285-7. PubMed ID: 9532041
    [No Abstract]   [Full Text] [Related]  

  • 12. Acute hypertension after renal allograft rejection therapy with OKT3 monoclonal antibody.
    Spieker C; Zidek W; Barenbrock M; Wieneke R; Buchholz B; Rahn KH
    J Int Med Res; 1991; 19(5):419-23. PubMed ID: 1748236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. OKT3 treatment for steroid-resistant acute rejection in kidney transplantation.
    Sevmis S; Emiroglu R; Karakayali F; Yagmurdur MC; Dalgic A; Moray G; Haberal M
    Transplant Proc; 2005 Sep; 37(7):3016-8. PubMed ID: 16213290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of acute cellular rejection with T10B9.1A-31 or OKT3 in renal allograft recipients.
    Waid TH; Lucas BA; Thompson JS; Brown SA; Munch L; Prebeck RJ; Jezek D
    Transplantation; 1992 Jan; 53(1):80-6. PubMed ID: 1531095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting factors of long-term results of OKT3 therapy for steroid resistant acute rejection following cadaveric renal transplantation.
    Rostaing L; Chabannier MH; Modesto A; Rouzaud A; Cisterne JM; Tkaczuk J; Durand D
    Am J Nephrol; 1999; 19(6):634-40. PubMed ID: 10592356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression and distribution of thrombomodulin on endothelial cells in kidney transplants with acute vascular rejection.
    Yamaguchi Y; Onitsuka S; Horita S; Tanabe K; Yagisawa T; Kawaguchi H; Ito K; Toma S; Ota K
    Transplant Proc; 1997; 29(1-2):164-6. PubMed ID: 9122945
    [No Abstract]   [Full Text] [Related]  

  • 17. Monoclonal antibodies in renal transplantation: a review.
    Parlevliet KJ; Schellekens PT
    Transpl Int; 1992 Sep; 5(4):234-46. PubMed ID: 1418316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of a second course of OKT3 monoclonal anti-T cell antibody for treatment of renal allograft rejection.
    Norman DJ; Shield CF; Henell KR; Kimball J; Barry JM; Bennett WM; Leone M
    Transplantation; 1988 Oct; 46(4):523-9. PubMed ID: 3140448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proliferation rate of cells in the interstitial infiltrate in acute kidney allograft rejection.
    Olsen S; Hansen HE
    Transplant Proc; 1996 Feb; 28(1):502-3. PubMed ID: 8644329
    [No Abstract]   [Full Text] [Related]  

  • 20. Case 6: benefits and risks of OKT3 treatment in renal transplantation.
    First MR
    Transplantation; 2001 Sep; 72(6):1177-8. PubMed ID: 11584824
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.